mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer.

已完结 20 由 Luke 发布于 2026/7/30 10:04:37

DOI:10.1158/1541-7786.MCR-21-0545
作者：D. Casadevall, A. Hernández-Prat, Sara Garc A-Alonso, Oriol Arpí-Lluciá, S. Menéndez, Mengjuan Qin, Cristina Guardia, B. Morancho, Francisco Javier Sanchez-Mart N, S. Zazo, E. Gavilan, MohammadA S
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However

应助信息

14小时前

同学羊小

2f5567888bbc11f1a7a034735aa3bc31.pdf 已采纳

15小时前

Book学术机器人

2026/7/30 10:04:37 未找到该文献，机器人已退出，请等待人工下载

2026/7/30 10:04:37 Book学术AI机器人收到请求，开始寻找文献

2026/7/30 10:04:37 已向机器人发送请求

15小时前

Luke 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierAutomatic stem phenotyping in soybean using keypoint detection